Edwards Lifesciences (EW) Operating Income (2009 - 2026)

Edwards Lifesciences has reported Operating Income for 18 years, with the latest figure at $477.6 million in Q1 2026.

• For the quarter ending Q1 2026, Operating Income rose 20.97% year-over-year to $477.6 million; the trailing twelve-month figure through Mar 2026 stood at $1.3 billion (down 5.44% YoY), and the FY2025 full-year result was $1.3 billion, down 8.3% from the prior year.
• Operating Income for Q1 2026 stood at $477.6 million, up from $151.1 million in the prior quarter.
• The five-year high for Operating Income was $477.6 million in Q1 2026, with the low at $151.1 million in Q4 2025.
• Average Operating Income over 5 years is $352.0 million, with a median of $365.9 million recorded in 2023.
• Year-over-year, Operating Income jumped 75.42% in 2023 and sank 51.66% in 2025.
• Tracing EW's Operating Income over 5 years: stood at $197.7 million in 2022, then jumped by 75.42% to $346.8 million in 2023, then fell by 9.86% to $312.6 million in 2024, then slumped by 51.66% to $151.1 million in 2025, then surged by 216.08% to $477.6 million in 2026.
• The last three Operating Income figures came in at $477.6 million (Q1 2026), $151.1 million (Q4 2025), and $307.1 million (Q3 2025), per Business Quant data.

Peer Comparison